ADME is an acronym commonly used in pharmacokinetic (PK) studies and pharmacology that stands for Absorption, Distribution, Metabolism and Excretion. It describes the disposition of a pharmaceutical compound within an organism and is one of the traditional approaches towards early appraisal of factors that impact the success of a drug candidate in the subsequent preclinical, clinical and commercial phases of drug development. Today, however, ADME and PK studies are used in conjunction to design a rational approach to drug discovery and ADME/PK has become a mature discipline through the application of well-established in vitro and in vivo methodologies. These methodologies incorporating ADME/PK studies are available at NoAb BioDiscoveries, a state-of-the-art research facility that provides a wide range of innovative drug discovery services and tools designed to accelerate the drug development process. Through this range of specialized and proprietary services, NoAb BioDiscoveries helps to shape and optimize drug discovery research providing innovative tools that facilitate success and accelerate timelines. In this manner, optimal and viable drug candidates are produced in a timely manner ensuring your success!
Clients of NoAb BioDiscoveries are able to profile compounds for selection of the best candidates for further pre-clinical and clinical development as a result of in vivo and in vitro ADME/PK studies and gene expression assays. The team of experienced scientists at this renowned research facility is expert at designing the best strategy and protocols to suit any drug discovery need. ADME/PK studies are skillfully designed and performed as standard procedures or customized to each client's needs and involve using fully conscious animals that have been catheterized for drug administration and sample collection in adherence to strict scientific and ethical guidelines. To examine study records and studies previously done by NoAb BioDiscoveries, visit www.noabbiodiscoveries.com where detailed information is available on various case studies. A full list of the in-house services that include ADME/PK studies and gene expression is also available at www.noabbiodiscoveries.com.
The high quality and high efficiency ADME/PK profiling at NoAb BioDiscoveries helps to select and prioritize leads. Together with the results of toxicity evaluations, hits from high throughput screening can be developed into leads which can then be optimized into promising drug candidates. Through ADME/PK profiling such as cell permeability, plasma protein binding, cytochrome P450 subtypes inhibition, metabolic stability in hepatocytes and liver subcellular fractions, plasma stability, cytotoxicity and DTEx™ micro array-based technology, investigators have been able to survey the effects of drug treatments in pre-clinical and clinical models and identify potential drug candidates. NoAb BioDiscoveries is committed to continue on the path of premier drug discovery so as to consistently deliver the best results to its clients!
Trust NoAb BioDiscoveries to find you the most promising drug candidates using innovative technologies such as ADME/PK profiling in the shortest time possible and with the greatest efficiency. Nobody understands better than NoAb BioDiscoveries that its success is entirely dependent on your success. For more information on the extensive range of in vivo and in vitro services offered at the facility, visit www.noabbiodiscoveries.com or if you need a drug design strategy customized to your specifications, you can contact the research facility with details at info@noabbiodiscoveries.com.
